Periostin was, thus, recently used as a biomarker in a proof-of-concept study in SSc patients to assess the response to romilkimab (a monoclonal bispecific antibody against IL-4/IL-13), showing a trend toward reduction compared to placebo (24). This evidence concerns the gene IL4 and systemic sclerosis.